Role of biopsy sampling for diagnosis of early and progressed hepatocellular carcinoma

Best Practice and Research: Clinical Gastroenterology

Volumn 28, Issue 5, 2014, Pages 813-829

  Kim, Haeryoung ^a   Park, Young Nyun ^b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Biopsy; Hepatocellular carcinoma; Hepatocellular neoplasms; Liver; Pathology

Indexed keywords

BRIVANIB; EVEROLIMUS; LINIFANIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MOLECULAR MARKER; RAMUCIRUMAB; SORAFENIB; SUNITINIB;

BILE DUCT CARCINOMA; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CANCER TISSUE; CELL DENSITY; CHRONIC HEPATITIS; CLINICAL FEATURE; COMBINED HEPATOCELLULAR CHOLANGIOCARCINOMA; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DYSPLASIA; EARLY CANCER; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER ADENOMA; LIVER BIOPSY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FOCAL NODULAR HYPERPLASIA; LIVER NODULE; LIVER TUMOR; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PATHOLOGIST; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RISK FACTOR; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; TUMOR GROWTH; BIOPSY; DISEASE COURSE; EARLY DIAGNOSIS; PATHOLOGY;

BIOPSY; CARCINOMA, HEPATOCELLULAR; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; HUMANS; LIVER NEOPLASMS;

EID: 84921727596     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2014.08.012     Document Type: Review

References (46)

1. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology 2011; 53: 1020-2.
2. European Association for the Study of the Liver. EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.
3. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology 1995; 22: 983-93.
4. International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: A report of the international consensus group for hepatocellular neoplasia. Hepatology 2009; 49: 658-64.
5. Theise ND, Curado M, Franceschi S, Hytiroglou P, Kudo M, Park YN, et al. Hepatocellular carcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system. 4th ed. Lyon: IARC; 2010. p. 205-16.
6. Park YN. Update on precursor and early lesions of hepatocellular carcinomas. Arch Pathol Lab Med 2011; 135: 704-15.
7. Park YN, Yang CP, Fernandez GJ, Cubukcu O, Thung SN, Theise ND. Neoangiogenesis and sinusoidal "capillarization" in dysplastic nodules of the liver. Am J Surg Pathol 1998; 22: 656-62.
8. Kojiro M. Pathomorphologic characteristics of early-stage small hepatocellular carcinoma. In: Kojiro M, editor. Pathology of hepatocellular carcinoma. Malden, MA: Blackwell Publishing; 2006. p. 31-49.
9. Takayama T, Makuuchi M, Hirohashi S, Sakamoto M, Yamamoto J, Shimada K, et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology 1998; 28: 1241-6.
10. Kutami R, Nakashima Y, Nakashima O, Shiota K, Kojiro M. Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans. J Hepatol 2000; 33: 282-9.
11. Park YN, Kojiro M, Di Tommaso L, Dhillon AP, Kondo F, Nakano M, et al. Ductular reaction is helpful in defining early stromal invasion, small hepatocellular carcinomas, and dysplastic nodules. Cancer 2007; 109: 915-23.
12. Di Tommaso L, Destro A, Seok JY, Balladore E, Terracciano L, Sangiovanni A, et al. The application of markers (HSP70, GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol 2009; 50: 746-54.
13. Di Tommaso L, Franchi G, Park YN, Fiamengo B, Destro A, Morenghi E, et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 2007; 45: 725-34.
14. Abdul-Al HM, Makhlouf HR, Wang G, Goodman ZD. Glypican-3 expression in benign liver tissue with active hepatitis C: Implications for the diagnosis of hepatocellular carcinoma. Hum Pathol 2008; 39: 209-12.
15. Christa L, Simon MT, Flinois JP, Gebhardt R, Brechot C, Lasserre C. Overexpression of glutamine synthetase in human primary liver cancer. Gastroenterology 1994; 106: 1312-20.
16. Bioulac-Sage P, Balabaud C, Bedossa P, Scoazec JY, Chiche L, Dhillon AP, et al. Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update. J Hepatol 2007; 46: 521-7.
17. Di Tommaso L, Destro A, Fabbris V, Spagnuolo G, Laura Fracanzani A, Fargion S, et al. Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma. Hepatology 2011; 53: 1549-57.
18. Park YN, Chae KJ, Kim YB, Park C, Theise N. Apoptosis and proliferation in hepatocarcinogenesis related to cirrhosis. Cancer 2001; 92: 2733-8.
19. Cai MY, Tong ZT, Zheng F, Liao YJ, Wang Y, Rao HL, et al. EZH2 protein: A promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies. Gut 2011; 60: 967-76.
20. Tatrai P, Somoracz A, Batmunkh E, Schirmacher P, Kiss A, Schaff Z, et al. Agrin and CD34 immunohistochemistry for the discrimination of benign versus malignant hepatocellular lesions. Am J Surg Pathol 2009; 33: 874-85.
21. Govaere O, Komuta M, Berkers J, Spee B, Janssen C, de Luca F, et al. Keratin 19: A key role player in the invasion of human hepatocellular carcinomas. Gut 2014; 63: 674-85.
22. Kim H, Choi GH, Na DC, Ahn EY, Kim GI, Lee JE, et al. Human hepatocellular carcinomas with "Stemness"-related marker expression: Keratin 19 expression and a poor prognosis. Hepatology 2011; 54: 1707-17.
23. Tsuchiya K, Komuta M, Yasui Y, Tamaki N, Hosokawa T, Ueda K, et al. Expression of keratin 19 is related to high recurrence of hepatocellular carcinoma after radiofrequency ablation. Oncology 2011; 80: 278-88.
24. Kim H, Yoo JE, Cho JY, Oh BK, Yoon YS, Han HS, et al. Telomere length, TERT and shelterin complex proteins in hepatocellular carcinomas expressing "stemness"-related markers. J Hepatol 2013; 59: 746-52.
25. Di Tommaso L, Sangiovanni A, Borzio M, Park YN, Farinati F, Roncalli M. Advanced precancerous lesions in the liver. Best Pract Res Clin Gastroenterol 2013; 27: 269-84.
26. Stoot JH, Coelen RJ, De Jong MC, Dejong CH. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: A systematic review including more than 1600 adenoma cases. HPB (Oxford) 2010; 12: 509-22.
27. Evason KJ, Grenert JP, Ferrell LD, Kakar S. Atypical hepatocellular adenoma-like neoplasms with beta-catenin activation show cytogenetic alterations similar to well-differentiated hepatocellular carcinomas. Hum Pathol 2013; 44: 750-8.
28. Bedossa P, Burt AD, Brunt EM, Callea F, Clouston AD, Dienes HP, et al. Well-differentiated hepatocellular neoplasm of uncertain malignant potential: Proposal for a new diagnostic category. Hum Pathol 2014; 45: 658-60.
29. Lagana SM, Salomao M, Bao F, Moreira RK, Lefkowitch JH, Remotti HE. Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma. Appl Immunohistochem Mol Morphol 2013; 21: 170-6.
30. Liu TC, Vachharajani N, Chapman WC, Brunt EM. Noncirrhotic hepatocellular carcinoma: Derivation from hepatocellular adenoma? Clinicopathologic analysis. Mod Pathol 2014; 27: 420-32.
31. Nault JC, Bioulac-Sage P, Zucman-Rossi J. Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology 2013; 144: 888-902.
32. Theise ND, Nakashima O, Park YN, Nakanuma Y. Combined hepatocellular-cholangiocarcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system. 4th ed. Lyon: IARC; 2010. p. 225-7.
33. Radwan NA, Ahmed NS. The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1. Diagn Pathol 2012; 7: 149.
34. Ushiku T, Shinozaki A, Shibahara J, Iwasaki Y, Tateishi Y, Funata N, et al. SALL4 represents fetal gut differentiation of gastric cancer, and is diagnostically useful in distinguishing hepatoid gastric carcinoma from hepatocellular carcinoma. Am J Surg Pathol 2010; 34: 533-40.
35. Nault JC, De Reynies A, Villanueva A, Calderaro J, Rebouissou S, Couchy G, et al. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology 2013; 145: 176-87.
36. Boyault S, Rickman DS, de Reynies A, Balabaud C, Rebouissou S, Jeannot E, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007; 45: 42-52.
37. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009; 69: 7385-92.
38. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004; 40: 667-76.
39. Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res 2010; 70: 10202-12.
40. van Malenstein H, Gevaert O, Libbrecht L, Daemen A, Allemeersch J, Nevens F, et al. A seven-gene set associated with chronic hypoxia of prognostic importance in hepatocellular carcinoma. Clin Cancer Res 2010; 16: 4278-88.
41. Kim H, Shim HS, Kim L, Kim TJ, Kwon KY, Lee GK, et al. Guideline recommendations for testing of gene rearrangement in lung cancer: A proposal of the Korean cardiopulmonary pathology study group. Korean J Pathol 2014; 48: 1-9.
42. Perez EA, Cortes J, Gonzalez-Angulo AM, Bartlett JM. HER2 testing: Current status and future directions. Cancer Treat Rev 2014; 40: 276-84.
43. Finn RS. Emerging targeted strategies in advanced hepatocellular carcinoma. Semin Liver Dis 2013; 33 (Suppl. 1) : S11-9.
44. Horwitz E, Stein I, Andreozzi M, Nemeth J, Shoham A, Pappo O, et al. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. Cancer Discov 2014; 4: 730-43.
45. Finn RS. Current and future treatment strategies for patients with advanced hepatocellular carcinoma: Role of mTOR inhibition. Liver Cancer 2012; 1: 247-56.
46. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359: 1995-2004.